

# William E Brady

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11248248/william-e-brady-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22  
papers

1,357  
citations

16  
h-index

22  
g-index

22  
ext. papers

1,544  
ext. citations

5.9  
avg, IF

3.71  
L-index

#	Paper	IF	Citations
22	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. <i>Lancet, The</i> , <b>2022</b> , 399, 541-553	4.0	7
21	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , <b>2020</b> , 158, 562-569	4.9	15
20	Clinical trial methodology in rare gynecologic tumor research: Strategies for success. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 605-611	4.9	4
19	Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 253-260	4.9	15
18	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 202-207	4.9	7
17	Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 9-13	4.9	28
16	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 300-309	4.9	22
15	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 243-249	4.9	44
14	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1955-1966	12.9	18
13	A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 204-9	4.9	35
12	Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. <i>Cancer</i> , <b>2016</b> , 122, 230-7	6.4	69
11	A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. <i>Gynecologic Oncology</i> , <b>2014</b> , 133, 537-41	4.9	22
10	Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 134-40	21.7	270
9	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , <b>2006</b> , 3, 93-102	3.3	61
8	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 2041-53	2.5	91
7	Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. <i>Mayo Clinic Proceedings</i> , <b>2006</b> , 81, 1177-85	6.4	23
6	A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. <i>Mayo Clinic Proceedings</i> , <b>2005</b> , 80, 587-95	6.4	212

5	Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. <i>Current Medical Research and Opinion</i> , <b>2005</b> , 21, 1123-30	25	31
4	LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. <i>MedGenMed: Medscape General Medicine</i> , <b>2005</b> , 7, 3		3
3	Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. <i>American Journal of Cardiology</i> , <b>2004</b> , 93, 1487-94	3	159
2	Human serum carotenoid concentrations are related to physiologic and lifestyle factors. <i>Journal of Nutrition</i> , <b>1996</b> , 126, 129-37	4.1	174
1	Influence of using different sources of carotenoid data in epidemiologic studies. <i>Journal of the American Dietetic Association</i> , <b>1996</b> , 96, 1271-5		47